Omnia Medical
Private Company
Total funding raised: $1.8M
Overview
Omnia Medical is a U.S.-based orthopedic implant company focused on spine and pain intervention, with a commercial portfolio of FDA-cleared devices. The company emphasizes engineering-driven innovation to create reproducible instrumentation for surgeons, targeting improved patient outcomes and cost savings for healthcare systems. Recent milestones include the 2025 FDA clearance and commercial launch of its PsiF DNA SI Joint Stabilization System and the resolution of significant litigation with a competitor. Omnia operates with a direct sales and distributor model, seeking to expand its commercial footprint in the competitive spine device market.
Technology Platform
Engineering-driven design of reproducible spinal implant systems and surgical instrumentation, focusing on biomechanics and workflow efficiency.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Omnia competes in the crowded spinal implant market against giants like Medtronic, Stryker, and Johnson & Johnson's DePuy Synthes, as well as pure-play spine companies like NuVasive, Globus Medical, and SeaSpine. In the SI joint niche, it faces competitors like SI-BONE, Medtronic (with the IFuse system), and other smaller firms, making differentiation through product design and surgeon relationships critical.